Last reviewed · How we verify
Mavenclad®
Mavenclad (cladribine) is a purine nucleoside analog that depletes lymphocytes by interfering with DNA synthesis and repair in dividing cells.
Mavenclad (cladribine) is a purine nucleoside analog that selectively depletes lymphocytes, particularly CD4+ and CD8+ T cells and B cells, to reduce autoimmune activity. Used for Relapsing-remitting multiple sclerosis (RRMS), Active secondary progressive multiple sclerosis (SPMS).
At a glance
| Generic name | Mavenclad® |
|---|---|
| Also known as | Cladribine |
| Sponsor | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany |
| Drug class | Purine nucleoside analog; immunosuppressant |
| Target | Deoxyadenosine kinase; DNA synthesis and repair pathways in lymphocytes |
| Modality | Small molecule |
| Therapeutic area | Immunology; Neurology |
| Phase | FDA-approved |
Mechanism of action
Cladribine is a deoxyadenosine analog that accumulates in lymphocytes and is phosphorylated to its active triphosphate form, which inhibits ribonucleotide reductase and disrupts DNA synthesis. This leads to selective depletion of B and T lymphocytes, reducing the autoimmune response. The drug has prolonged effects due to sustained lymphocyte depletion following short treatment courses.
Approved indications
- Relapsing-remitting multiple sclerosis (RRMS)
- Active secondary progressive multiple sclerosis (SPMS)
Common side effects
- Lymphopenia
- Upper respiratory tract infection
- Headache
- Nausea
- Herpes zoster
- Thrombocytopenia
Key clinical trials
- Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) (PHASE3)
- ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis (PHASE2, PHASE3)
- Randomized Autologous heMatopoietic Stem Cell Transplantation Versus Alemtuzumab, Cladribine or Ocrelizumab for RRMS (RAM-MS) (PHASE3)
- Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS)
- Extension to the MAGNIFY MS Trial on Mavenclad® (Magnify MS Extension) (PHASE4)
- Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS)
- Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension) (PHASE4)
- Effects of Oral Cladribine on Remyelination and Inflammation in Multiple Sclerosis Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |